catumaxomab
- Product Name
- catumaxomab
- CAS No.
- 509077-98-9
- Chemical Name
- catumaxomab
- Synonyms
- catumaxomab;Research Grade Catumaxomab;Research Grade Catumaxomab (DHD17406)
- CBNumber
- CB41508594
- Formula Weight
- 0
- MOL File
- Mol file
catumaxomab Property
- form
- Liquid
- color
- Colorless to light yellow
catumaxomab Chemical Properties,Usage,Production
Description
Catumaxomab is an anti-Ep-CAM monoclonal antibody, it has been designed to induce more efficient killing of epithelial tumor cells. More specifically, catumaxomab is a bispecific trifunctional antibody (trAb). In addition to its EpCAM recognition arm, it possesses an anti-CD3 arm that targets the T-cell antigen CD3; binding to the CD3 receptor activates T cells to release cytotoxic cytokines and to promote T cell-mediated lysis. In essence, catumaxomab consists of one half of an anti-Ep-CAM antibody and one half of an anti-CD3 antibody. The trifunctionality comes into play with an intact Fc region that selectively binds to FCg receptor-positive accessory cells, such as macrophages, dendritic cells, and natural killer (NK) cells that promote phagocytosis and antibody-dependent cell cytotoxicity. As a trAb that brings the requisite immune effector cells in close proximity to the tumor cells, catumaxomab destroys tumor cells possessing the surface antigen Ep-CAM via simultaneous activation and complex crosstalk of T cells and accessory immune cells. While it has gained approval for the intraperitoneal (i.p.) treatment of malignant ascites caused by Ep-CAM-positive metastatic epithelial-derived tumors, it is also being evaluated for the treatment of ovarian and gastric cancers.
Originator
TRION Pharma (Germany)
Uses
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers[1][2].
brand name
Removab
References
[1] Mansoor M. Amiji, et.al. Chapter Two - Innate and adaptive immunity in cancer. Cancer Immunology and Immunotherapy. Academic Press, 2022, Pages 19-61.
[2] Hirschhaeuser F, et.al. Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action. Cancer Immunol Immunother. 2010 Nov;59(11):1675-84. DOI:10.1007/s00262-010-0894-1
catumaxomab Preparation Products And Raw materials
Raw materials
Preparation Products
catumaxomab Suppliers
- Tel
- 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
- Fax
- +86-27-87599188
- Country
- China
- ProdList
- 1493
- Advantage
- 55
- Tel
- Fax
- -
- eric_feng1954@126.com
- Country
- China
- ProdList
- 9248
- Advantage
- 55
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 17316404525 17316404525
- 209533805@qq.com
- Country
- China
- ProdList
- 9765
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6739
- Advantage
- 58